Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics - influenza a viruses belong to the orthomyxoviridae family, and have a negative-sense, segmented RNA…

Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics - influenza a viruses belong to the orthomyxoviridae family, and have a negative-sense, segmented RNA genome, which can cause seasonal or pandemic flu with high morbidity and significant mortality. Vaccination is the most prevalent prophylactic means for controlling influenza infections. However, an effective vaccine usually takes at least six months to develop. Furthermore, vaccination has limited effectiveness in the treatment of immunocompromised patients, and its effectiveness is also limited during a pandemic. The current therapeutic options for flu infections are all based on the neuraminidase inhibitors (nais; oseltamivir, zanamivir and peramivir), while the influenza M2 ION channel blockers (amantadine and rimantadine) are not now recommended since all of the circulating influenza strains have acquired resistance. (xofluza, a polymerase acidic endonuclease inhibitor, has just been approved in 2018 and is yet untried during a flu season.) the rapid emergence of the NAI-resistant strains of influenza a viruses strongly suggests that nais alone may not be sufficient as effective therapies, and thus new treatment options targeting the other viral/host factors are urgently needed. This application defines a plan to develop potent, small molecule inhibitors, which block entry of influenza a viruses. We have identified compounds that inhibit entry of infectious influenza a viruses, with IC50 values in the nanomolar range. We have synthesized structurally diverse analogs of the anti-influenza HIT series using structure-activity relationships (sars) to improve potency and selectivity; validated the lead inhibitor candidates in the infectious assay and investigated the mechanism of action (MOA) of the these inhibitors; and selected anti-influenza inhibitors with excellent in vitro potency and selectivity values and druglike in vivo pharmacokinetic properties. In this fast track sttr phase i &II application, we propose four specific aims: (1) optimize the lead scaffold and select development candidates; (2) investigate the mechanism of action (MOA) of the advanced lead compounds with HA proteins; (3) evaluate the pharmacokinetics/toxicokinetics of the advanced lead compounds; and (4) preclinical development.